Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TF-002
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
TF-002 is a small molecule drug with mast cell stabilizing activity. It inhibits the formation of lipid rafts in mast cell membranes, which are essential for the signaling processes that trigger the release of allergic and inflammatory mediators from mast cells. By preventing this process, TF-002 may reduce symptoms associated with conditions involving abnormal mast cell activation, such as cutaneous mastocytosis[1][2].
- Other names
- mast cell stabilizer TF002
Beyond the preview
Go deeper on TF-002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TF-002.